Lumexa Imaging (LMRI) Q4 2025 Earnings Transcript
Key takeaways
- Need a quote from a Motley Fool analyst?
- Good morning, and thank you all for joining us today on our first earnings call as a public company.
- We advanced our growth plans, achieving a record number of de novo openings and driving strong same-center growth.
Need a quote from a Motley Fool analyst? Email pr@fool.com
Caitlin Zulla: Thanks, Sue. Good morning, and thank you all for joining us today on our first earnings call as a public company. The fourth quarter of 2025 marked a strong close to an important year for Lumexa Imaging, and we delivered steady and consistent growth in revenue and EBITDA that exceeds our preliminary earnings announcement. We generated consolidated revenue of $267.7 million, up 7.9% over Q4 of last year. Adjusted EBITDA of $63.8 million represented an 18.6% increase over Q4 of last year and delivered a 23.8% adjusted EBITDA margin. We completed 1.4 million advanced imaging exams system-wide in the quarter, which is a 7.7% increase year-over-year. 2025 was a year marked by several meaningful achievements for Lumexa Imaging.
Here are a few of the highlights. We advanced our growth plans, achieving a record number of de novo openings and driving strong same-center growth. We launched a successful rebrand of the company, rolling out our new name, Lumexa Imaging to better represent our shared purpose, our innovative spirit and our commitment to bringing greater access and exceptional care to more patients and more communities. We completed our IPO, bringing greater awareness of our company to the investment community, broadening access to our value creation opportunity and by using proceeds to reduce our leverage profile, freeing up more cash to support our plans for profitable growth.